1. Home
  2. OGEN vs GNPX Comparison

OGEN vs GNPX Comparison

Compare OGEN & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.16

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

SELL

Current Price

$1.52

Market Cap

2.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OGEN
GNPX
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.2M
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
OGEN
GNPX
Price
$0.16
$1.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 246.6K
103.0K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.42
52 Week High
$1.11
$9.99

Technical Indicators

Market Signals
Indicator
OGEN
GNPX
Relative Strength Index (RSI) 14.14 28.46
Support Level N/A $0.80
Resistance Level $0.59 $2.42
Average True Range (ATR) 0.03 0.19
MACD -0.02 -0.03
Stochastic Oscillator 10.60 1.11

Price Performance

Historical Comparison
OGEN
GNPX

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: